scholarly journals A case in which a hemodialysis patient was diagnosed with papillary thyroid carcinoma and parathyroid oxyphil cell adenoma during secondary hyperparathyroidism surgery

2020 ◽  
Vol 53 (2) ◽  
pp. 85-91
Author(s):  
Kazuhiko Kato ◽  
Taketo Uchiyama ◽  
Akiko Tajiri ◽  
Ryo Kikuchi ◽  
Yasuo Toriumi ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Secondary Hyperparathyroidism ◽  
Hemodialysis Patient ◽  
Papillary Thyroid ◽  
Cell Adenoma ◽  
Oxyphil Cell

scholarly journals A Retrospective Case-control Study of Tumor Characteristics of Coexistent Papillary Thyroid Carcinoma Diagnosed in Surgically Treated Patients for Secondary Hyperparathyroidism: Higher Incidence and More Often Occult Papillary Thyroid Carcinoma

2020 ◽  
Author(s):  
Junhao Ma ◽  
Zhuochao Mao ◽  
Yimin Lu ◽  
Haohao Wang ◽  
Jun Yang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
General Population ◽  
Thyroid Carcinoma ◽  
Secondary Hyperparathyroidism ◽  
Extrathyroidal Extension ◽  
Tumor Characteristics ◽  
Papillary Thyroid ◽  
Pathological Subtype ◽  
Significant Difference

Abstract Background :Coexistence of primary hyperparathyroidism (PHPT) and PTC is common and may be associative with more aggressive papillary thyroid carcinoma (PTC) for higher rates of extrathyroidal extension and multicentricity. However, it remains unclear whether secondary hyperparathyroidism (SHPT) accounts for more invasive PTC in terms of morbidity, tumor pathological characteristics and prognosis . The aim of this study was to evaluate the rate and tumor characteristics of PTC in patients operated for secondary hyperparathyroidism (SHPT).Methods:A total of 531 patients with PTC who underwent surgery were evaluated retrospectively from January 2013 to December 2018 in the first affiliated hospital of the Zhejiang University. Patient demographics, operative and postoperative outcomes were recorded and analyzed. Among them, 34 patients of co-occurrence of secondary hyperparathyroidism and papillary thyroid carcinoma (PTC+SHPT) were enrolled. Control subjects were derived through 1:4 matching for age, sex and gender pathological subtype. 34 patients of co-occurrence of secondary hyperparathyroidism and papillary thyroid carcinoma (PTC+SHPT) were selected as control group after matching 1:4 for age, gender and pathological subtype.Results:There were 34 patienst coexisting with PTC+SHPT among the 531 surgery patients of SHPT(6.4%). Mean tumor diameter of group PTC+SHPT was smaller than that in group PTC (5.57mm vs 9.00mm, p=0.000). The proportion of papillary thyroid microcarcinoma(PTMC，means PTC with a diameter smaller than 10 mm) in group PTC+SHPT were significantly higher than that in group PTC [29 (85.29%) vs 86 (63.24%), P=0.014]. There were no statistically significant difference among the tumor multicentricity [15 (44.12%) vs 39 (28.68%), P=0.066], tumor bilaterally [9(26.47%) vs29(21.32%), P=0.499]，tumor extrathyroidal extension [2(5.88%) vs19 (13.97%), P=0.255] and lymph node metastasises rate [12 (35.29%) vs 49 (36.03%), P=1.000]. We found differences between group PTC+SHPT and group PTC patients with respect to contralateral thyroidectomy [10 (29.41%) vs 70(51.47%), P=0.023] and lymph node dissection [22 (64.71%) vs 125(91.91%), P=0.000].There was no significant difference between group PTC+SHPT and group PTC in prognostic staging [33 (97.06%) vs 122 (89.71%), P=0.309] and recurrence [mean follow-up time 36 months vs 39 months, P=0.33].Conclusions: The prevalence of PTC is higher in patients with SHPT than in the general population. Compared with PTC in the general population, most of PTC with SHPT are occult thyroid carcinoma and present no significant difference in tumor multicentricity, tumor bilaterally,tumor extrathyroidal extension, lymph node metastasises and prognostic staging. It’s necessary for surgeons to make more adequate preoperative prediction and do more careful examination during the surgery in case of missing the coexistence of PTC in SHPT patients.

scholarly journals Coexistence of papillary thyroid carcinoma in secondary hyperparathyroidism

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Junhao Ma ◽  
Zhuochao Mao ◽  
Yunjin Yao ◽  
Yimin Lu ◽  
Haohao Wang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Secondary Hyperparathyroidism ◽  
Extrathyroidal Extension ◽  
Tumor Diameter ◽  
Papillary Thyroid ◽  
Thyroid Carcinomas ◽  
Significant Difference

Abstract Background The coexistence of primary hyperparathyroidism and papillary thyroid carcinoma (PTC) is common and may be associative with more aggressive PTC, with higher rates of extrathyroidal extension and multicentricity. However, it is unclear whether secondary hyperparathyroidism (SHPT) is associated with more invasive PTC in terms of morbidity, tumor pathological characteristics, and prognosis. The aim of this study was to evaluate the rate and tumor characteristics of PTC in patients with SHPT. Methods A total of 531 patients diagnosed with SHPT who underwent surgery from August 2013 to December 2018 at the First Affiliated Hospital of Zhejiang University were evaluated retrospectively. Patient demographics, surgical records, and follow-up information were recorded and analyzed. Control subjects were matched to the enrolled patients in a 1:4 ratio in terms of age, sex and pathological subtype. Results Among the 531 patients with SHPT who underwent surgery, 34 had coexisting PTC and PTC + SHPT (6.4%). The mean tumor diameter in the PTC + SHPT group was smaller than that in the PTC group (5.57 mm vs 9.00 mm, p < 0.001). The proportion of papillary thyroid micro-carcinoma in the PTC + SHPT group was significantly higher than that in the PTC group (29 [85.29%] vs. 86[63.24%], p = 0.014). There were no statistically significant differences between groups in terms of tumor multicentricity (15 [44.12%] vs 39 [28.68%], p = 0.066), tumor bilaterality (9 [26.47%] vs. 29 [21.32%], p = 0.499), tumor extrathyroidal extension (2 [5.88%] vs. 19 [13.97%], p = 0.255), or lymph node (LN) metastasis rate (12 [35.29%] vs. 49 [36.03%], p = 1.000). However, the PTC + SHPT and PTC groups were significantly different in terms of contralateral thyroidectomy (10 [29.41%] vs. 70 [51.47%], p = 0.023) and lymph node dissection (22 [64.71%] vs. 125 [91.91%], p < 0.001).There was no significant difference between the PTC + SHPT and PTC groups in terms of prognostic staging (33 [97.06%] vs. 122 [89.71%], p = 0.309) or recurrence (mean follow-up time: 36 months vs. 39 months, p = 0.33). Conclusions The prevalence of PTC is high in patients with SHPT; compared with PTC in the general population, most papillary thyroid carcinomas with SHPT are occult thyroid carcinomas and present no significant difference in terms of tumor pathological features and prognostic staging. It is necessary for surgeons to perform more adequate preoperative examination and be more careful during surgery to avoid missing the coexistence of PTC in patients with SHPT.

scholarly journals SP570CALCIPHYLAXIS ASSOCIATED WITH PAPILLARY THYROID CARCINOMA AND SECONDARY HYPERPARATHYROIDISM IN A HAEMODIALYSIS PATIENT: A CASE REPORT

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i540-i540
Author(s):  
Nicola Giotta ◽  
Daniele Ricci ◽  
Angela Maria Marino ◽  
Annalisa Gonnella ◽  
Martina Ferraresi ◽  
...  
Keyword(s):  
Case Report ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Secondary Hyperparathyroidism ◽  
Haemodialysis Patient ◽  
Papillary Thyroid

scholarly journals Coexistence of Papillary Thyroid Carcinoma in Secondary Hyperparathyroidism

2021 ◽  
Author(s):  
Junhao Ma ◽  
Zhuochao Mao ◽  
Yunjin Yao ◽  
Yimin Lu ◽  
Haohao Wang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Secondary Hyperparathyroidism ◽  
Extrathyroidal Extension ◽  
Careful Examination ◽  
Papillary Thyroid ◽  
Pathological Subtype ◽  
Significant Difference

Abstract Background: Coexistence of primary hyperparathyroidism and papillary thyroid carcinoma is common and may be associative with more aggressive papillary thyroid carcinoma for higher rates of extrathyroidal extension and multicentricity. However, it remains unclear whether secondary hyperparathyroidism accounts for more invasive papillary thyroid carcinoma in terms of morbidity, tumor pathological characteristics and prognosis. The aim of this study was to evaluate the rate and tumor characteristics of papillary thyroid carcinoma in patients of SHPT.Methods: A total of 531 patients diagnosed of SHPT and underwent surgery were evaluated retrospectively from January 2013 to December 2018 in the first affiliated hospital of the Zhejiang University. Patients’ demographics, operation records and follow-up information were recorded and analyzed. Among them, 34 patients had PTC concurrent with SHPT (PTC+SHPT) were enrolled. Control subjects were derived through 1:4 matching for age, sex and gender pathological subtype. 136 patients of papillary thyroid carcinoma were selected as control group after matching 1:4 for age, gender and pathological subtype.Results: There were 34 patients coexisting with PTC+SHPT among the 531 surgery patients diagnosed as SHPT (6.4%). Mean tumor diameter of PTC+SHPT group was smaller than that in PTC group(5.57mm vs 9.00mm, p＜0.001). The proportion of papillary thyroid micro-carcinoma in PTC+SHPT group were significantly higher than that in PTC group [29 (85.29%) vs 86 (63.24%), P=0.014]. There were no statistically significant difference among the tumor multicentricity [15 (44.12%) vs 39 (28.68%), P=0.066], tumor bilaterality [9(26.47%) vs29(21.32%), P=0.499]，tumor extrathyroidal extension [2(5.88%) vs19 (13.97%), P=0.255] and lymph node metastasizes rate [12 (35.29%) vs 49 (36.03%), P=1.000]. We found differences between PTC+SHPT group and PTC group patients with respect to contralateral thyroidectomy [10 (29.41%) vs 70(51.47%), P=0.023] and lymph node dissection [22 (64.71%) vs 125(91.91%), P＜0.001].There was no significant difference between PTC+SHPT group and PTC group in prognostic staging [33 (97.06%) vs 122 (89.71%), P=0.309] and recurrence [mean follow-up time 36 months vs 39 months, P=0.33].Conclusions: The prevalence of PTC is high in patients with SHPT. Compared with PTC in the general population, most of PTC with SHPT are occult thyroid carcinoma and present no significant difference in tumor pathological features and prognostic staging. It is necessary for surgeons to make more adequate preoperative prediction and do more careful examination during the surgery in case of missing the coexistence of PTC in SHPT patients.

scholarly journals Synchronous papillary thyroid carcinoma and secondary hyperparathyroidism: Report of cases and review of the literature

2005 ◽  
Vol 41 (4) ◽  
pp. 74-76 ◽  
Author(s):  
Faissal Tarrass ◽  
Samira Daki ◽  
Meryem Benjelloun ◽  
Benyounes Ramdani ◽  
Mohamed Garbi Benghanem ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Secondary Hyperparathyroidism ◽  
Papillary Thyroid ◽  
Review Of The Literature

Papillary Thyroid Carcinoma: How Radical Lymphadenectomy Should be Performed?

Swiss Surgery ◽  
2003 ◽  
Vol 9 (2) ◽  
pp. 63-68
Author(s):  
Schweizer ◽  
Seifert ◽  
Gemsenjäger
Keyword(s):  
High Risk ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Low Risk ◽  
Papillary Thyroid ◽  
Sentinel Nodes ◽  
Fand Sich ◽  
Radical Lymphadenectomy ◽  
N Status

Fragestellung: Die Bedeutung von Lymphknotenbefall bei papillärem Schilddrüsenkarzinom und die optimale Lymphknotenchirurgie werden kontrovers beurteilt. Methodik: Retrospektive Langzeitstudie eines Operateurs (n = 159), prospektive Dokumentation, Nachkontrolle 1-27 (x = 8) Jahre, Untersuchung mit Bezug auf Lymphknotenbefall. Resultate: Staging. Bei 42 Patienten wurde wegen makroskopischem Lymphknotenbefall (cN1) eine therapeutische Lymphadenektomie durchgeführt, mit pN1 Status bei 41 (98%) Patienten. Unter 117 Patienten ohne Anhalt für Lymphknotenbefall (cN0) fand sich okkulter Befall bei 5/29 (17%) Patienten mit elektiver (prophylaktischer) Lymphadenektomie, und bei 2/88 (2.3%) Patienten ohne Lymphadenektomie (metachroner Befall) (p < 0.005). Lymphknotenrezidive traten (1-5 Jahre nach kurativer Primärtherapie) bei 5/42 (12%) pN1 und bei 3/114 (2.6%) cN0, pN0 Tumoren auf (p = 0009). Das 20-Jahres-Überleben war bei TNM I + II (low risk) Patienten 100%, d.h. unabhängig vom N Status; pN1 vs. pN0, cN0 beeinflusste das Überleben ungünstig bei high risk (>= 45-jährige) Patienten (50% vs. 86%; p = 0.03). Diskussion: Der makroskopische intraoperative Lymphknotenbefund (cN) hat Bedeutung: - Befall ist meistens richtig positiv (pN1) und erfordert eine ausreichend radikale, d.h. systematische, kompartiment-orientierte Lymphadenektomie (Mikrodissektion) zur Verhütung von - kurablem oder gefährlichem - Rezidiv. - Okkulter Befall bei unauffälligen Lymphknoten führt selten zum klinischen Rezidiv und beeinflusst das Überleben nicht. Wir empfehlen eine weniger radikale (sampling), nur zentrale prophylaktische Lymphadenektomie, ohne Risiko von chirurgischer Morbidität. Ein empfindlicherer Nachweis von okkultem Befund (Immunhistochemie, Schnellschnitt von sampling Gewebe oder sentinel nodes) erscheint nicht rational. Bei pN0, cN0 Befund kommen Verzicht auf 131I Prophylaxe und eine weniger intensive Nachsorge in Frage.

Sign in / Sign up

Export Citation Format

Share Document